Trial intelligence / Profile preview

Exergaming and Mediterranean Diet in Thyroid Cancer Patients Post-Thyroidectomy

NCT05265819Completed

Start
Mar 2022
Primary completion
Jul 2025
Countries
1
01

Overview

Randomised, open-label trial in thyroid cancer (4 arms). Primary endpoints: CD3- Natural Killer Cells at 3 months, CD16+ Natural Killer Cells at 3 months and 1 more. Started Mar 2022; status: completed.

02

Conditions

thyroid cancer

Beyond the preview

Go deeper on NCT05265819.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05265819.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call